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Abstract
Background: We have previously shown the high prevalence of oral anti-human papillomavirus type 16 (HPV-16)
antibodies in women with HPV-associated cervical neoplasia. It was postulated that the HPV antibodies were initiated
after HPV antigenic stimulation at the cervix via the common mucosal immune system. The present study aimed to
further evaluate the effectiveness of oral fluid testing for detecting the mucosal humoral response to HPV infection and
to advance our limited understanding of the immune response to HPV.
Methods: The prevalence of oral HPV infection and oral antibodies to HPV types 16, 18 and 11 was determined in a
normal, healthy population of children, adolescents and adults, both male and female, attending a dental clinic. HPV types
in buccal cells were determined by DNA sequencing. Oral fluid was collected from the gingival crevice of the mouth by
the OraSure method. HPV-16, HPV-18 and HPV-11 antibodies in oral fluid were detected by virus-like particle-based
enzyme-linked immunosorbent assay. As a reference group 44 women with cervical neoplasia were included in the study.
Results: Oral HPV infection was highest in children (9/114, 7.9%), followed by adolescents (4/78, 5.1%), and lowest in
normal adults (4/116, 3.5%). The predominant HPV type found was HPV-13 (7/22, 31.8%) followed by HPV-32 (5/22,
22.7%). The prevalence of oral antibodies to HPV-16, HPV-18 and HPV-11 was low in children and increased substantially
in adolescents and normal adults. Oral HPV-16 IgA was significantly more prevalent in women with cervical neoplasia
(30/44, 68.2%) than the women from the dental clinic (18/69, 26.1% P = 0.0001). Significantly more adult men than women
displayed oral HPV-16 IgA (30/47 compared with 18/69, OR 5.0, 95% CI 2.09–12.1, P < 0.001) and HPV-18 IgA (17/47
compared with 13/69, OR 2.4, 95% CI 0.97–6.2, P = 0.04).
Conclusion: The increased prevalence of oral HPV antibodies in adolescent individuals compared with children was
attributed to the onset of sexual activity. The increased prevalence of oral anti-HPV IgA in men compared with women
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was noteworthy considering reportedly fewer men than women make serum antibodies, and warrants further
investigation.
Background
The involvement of human papillomaviruses (HPV) in
squamous cell carcinomas of the anogenital region is
widely accepted. HPV infection has also been demon-
strated in several disorders of the oral and tonsillar
regions [1] but unlike cervical cancers where almost 100%
of tumours contain HPV DNA [2], only up to half of oral
and tonsillar cancers contain HPV DNA, the greater
majority with HPV types HPV-16 and HPV-18 [1]. HPV
has been reported present in normal buccal mucosa with
varying detection rates [3-5]. Oral HPV infection shows
the typical fluctuating presence observed in anogenital
mucosa [6].
Vaccines for the control of HPV infection are presently in
the process of being released for general use. In Africa with
its huge burden of HPV-associated cancers, novel vaccines
against HPV are under development that could enable the
vaccination of large sectors of the population [7]. The
introduction of appropriate vaccines to an area will
require knowledge of the HPV types within the general
population and those associated with cervical [8] and
other cancers. Vaccine introduction will also require mon-
itoring of the immune response in vaccinees during clini-
cal trials and then within a public health vaccine program
the testing of children and young people for exposure to
HPV prior to vaccination. Therefore, there is the need for
easy, safe, non-invasive sampling methods for the deter-
mination of HPV infection and of the immune responses
to HPV.
The testing of oral fluid for antibodies has proved most
useful as an HIV-1 screening tool as oral HIV-1 IgG anti-
bodies closely reflect HIV-1 serostatus [9]. The oral test
requires the insertion of a small absorbent pad into the
gingival crevice of the mouth for two minutes. Using this
sampling method, we previously described the presence
of oral fluid HPV-16 IgA and IgG antibodies in the major-
ity of women with cervical neoplasia [10]. In a small pilot
study we found that oral HPV-16 IgA, when compared
with serum and cervico-vaginal rinse antibodies, most
closely correlated with HPV-16 DNA at the cervical lesion
of women with cervical intraepithelial neoplasia (CIN)
[7] This indicated that oral IgA could be a useful biomar-
ker of mucosal HPV infection at a genital site via the com-
mon mucosal immune system [11]. Cameron et al., 2003
[12] reported a moderate correlation between oral and
serum HPV IgG antibodies in HIV-1 seropositive individ-
uals. Buchinsky et al., 2006 [13] aiming to evaluate oral
fluid testing in lieu of serum testing for HPV antibody sta-
tus, reported a concordance of oral fluid and serum anti-
bodies from college students but that oral antibody
detection was less sensitive than serum.
HPV seropositivity has been shown to be a biomarker of
past and present HPV infection and lifetime number of
sexual partners [14]. The presence of oral fluid HPV IgG
being mainly serum-derived [15] could conceivably serve
as a similar biomarker.
The present study aimed to evaluate the extent of oral HPV
infection and the prevalence of oral IgA and IgG antibod-
ies to HPV-16, HPV-18 and HPV-11 in members of a nor-
mal healthy population, male and female, children to
adult, and to assess the efficacy and acceptability of oral
fluid sampling for HPV testing in young children and
older individuals. To our knowledge the presence of HPV
antibodies in oral fluid have not previously been reported
in such populations. The study also hoped to further our
limited basic understanding of the immune response to
HPV infection in especially men who are being considered
for inclusion in HPV vaccination strategies as men sexu-
ally transmit HPV to their female partners[14]. Signifi-
cantly fewer men reportedly make serum HPV antibodies
than women [16-18] despite relatively higher rates of sex-
ual activity [16].
Methods
Study participants
Participants in the present study were visitors to dental
clinics in the Cape Town metropolitan area for normal
dental treatment during 2003(dental clinic population).
Informed consent or parental consent for the children was
obtained from all individuals and approval for the study
obtained from the Ethics Committee for Human Research
of the University of the Western Cape. There were 114
children (56 male, 58 female, aged 1–12 years, mean age
6 years), 78 adolescents (36 male, 42 female, aged 13–19
years, mean age 15.7 years) and 116 adults (47 male, 69
female, aged 20–61 years, mean age 28.8 years) with ade-
quate buccal samples who were included in the study. Fur-
ther participants were 44 women who formed part of
study investigating cervical immune responses to HPV-16
(Passmore et al., submitted for publication). The latter
women aged between 18 and 40 years were recruited dur-
ing 2004 and 2005 from amongst first time attendees of
the Colposcopy Clinic at Groote Schuur Hospital, Cape
Town, South Africa. Of the 44 women, 19 were diagnosed
by histology and/or colposcopy with high grade cervical
intraepithelial neoplasia (CIN2/3), 13 with low grade cer-BMC Infectious Diseases 2006, 6:95 http://www.biomedcentral.com/1471-2334/6/95
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vical disease (CIN1) and 12 had cleared their CIN (CIN0)
(colposcopy clinic, CC patients). The latter (CIN0) had
been referred to the colposcopy clinic with high grade cer-
vical disease as diagnosed by Pap smear but on subse-
quent histology or colposcopy or both showed no CIN.
Sample collection
Trained dentists collected buccal samples for HPV DNA
determinations by brushing the entire mucosa of both
inner cheeks with a CerviBrush (Digene). Brushes were
placed in sterile Digene tubes containing transport buffer.
Oral fluid samples were collected with an OraSure pad
(Epitope, Beaverton, OR) as described previously [10],
sampling predominately serum transudate in the gingival
crevice of the mouth. Oral fluid IgA collected by this
method is mainly saliva derived whereas oral IgG is pri-
marily from serum transudate [15]. The presence of any
oral lesion in the dental population was diagnosed by
consensus of at least two consultant dentists. The presence
of gingivitis was not assessed in any patient. From the CC
patients enrolled in the study, a Digene cervical sampler
obtained cervical cells and mucus from the endocervix for
HPV DNA and antibody determination and clotted
peripheral blood specimens were taken for the measure-
ment of serum antibody responses.
HPV DNA determinations
DNA was extracted and purified from buccal cells using
QIAamp DNA minikit (Qiagen) and buccal swab proto-
col. The quality of the DNA and thus the adequacy of the
buccal sample, was evaluated by amplifying a section of
the CCR-5 gene as described by Michael et al, (1997) [19].
The presence of oral HPV DNA in the dental population
was detected using degenerate primers [20] in a nested
polymerase chain reaction producing a 335 bp fragment
that was purified and sequenced. HPV typing was per-
formed on cervical cells from CC patients using a Roche
Reverse line blot hybridization assay according to the
manufacturers' instructions (Roche, USA). The Roche
reverse line blot hybridization assay has the capacity to
detect 37 different HPV genotypes (Oncogenic types:
HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, -53, -56,
-58, -59, -66, -67, -68, -69, -70, -73, -82, -IS39 [n = 22];
nononcogenic types: HPV-6, -11, -40, -42, -54, -55, -61, -
62, -64, -71, -72, -81, -83, -84, -CP6108 [n = 15]).
Virus-like particles
All virus-like particles (VLPs) for antibody enzyme-linked
immunosorbent assay (ELISA) were composed of major
capsid protein L1 only. HPV-18 VLPs were obtained from
MedImmune Inc (Gaithersburg, USA). HPV-16 and HPV-
11 VLPs were prepared using recombinant baculoviruses
expressing either HPV-11 or HPV-16 L1 protein to infect
monolayer cultures of Sf21 insect cells in twelve 75 cm2
tissue culture flasks, at an MOI of ~10. Cells were har-
vested by centrifugation at 5000 × g, 6 days post infection
[21]. The cell pellet was resuspended in 10 ml harvest
buffer (Dulbecco's PBS, Sigma, plus 0.4 g/ml CsCl) and
the cells lysed by sonication. The cell lysate was subjected
to isopycnic gradient ultracentrifugation at 100 000 × g for
24 hours at 20°C using a Beckman SW50.1 rotor. The
VLP-containing band was removed through the side of
each tube using a hypodermic needle and syringe. The
VLP preparations were then dialysed extensively against
dialysis buffer (PBS plus 400 mM NaCl) before being fro-
zen in aliquots at -80°C until use.
Antibody determination
A capture ELISA was used to detect oral HPV IgA and IgG
antibodies to HPV-16, HPV-18 and HPV-11. Oral fluid
and serum from CC patients were tested for HPV-16 anti-
bodies only. Serum antibody detection was by direct VLP-
16-based ELISA. ELISAs were a modification of that
described by Studentsov et al., 2002 [22], using polymer
solutions (Sigma) for blocking (polyvinyl alcohol, PVA)
and secondary antibody (polyvinylpyrrolidone, PVP)
enhancement. This enhanced ELISA enabled the use of
oral fluid at a 1:5 dilution instead of the previous 1:1 dilu-
tion [10] and serum at 1:100 dilution. Briefly, mono-
clonal antibodies H16.V5 directed against the major
conformational, neutralising epitope on HPV-16, H11 B3
against HPV-11 and H18 R5 against HPV-18 (kindly sup-
plied by N. Christensen, Milton Hershey Medical Centre,
USA) were used as capture antibodies. Plates were coated
with 100 μl monoclonal antibody at a dilution of 1:2000
in PBS pH 7.4 overnight at 4°C, washed twice with PBS
and blocked with 100 μl 0.05% PVA in PBS for 2 hours at
room temperature. Plates were washed six times with PBS
and wells filled with 100 μl of 0.05 μg virus-like particle
(VLP) to HPV-16, HPV-11 and HPV-18 in PBS for 1 hr at
37°. After washing plates six times, oral or cervical fluid
diluted 1:5 in 0.5% PVA was added and allowed to incu-
bate at 40°C overnight. Subsequent procedures were as
described for other ELISAs [10] but using 0.8% PVP and
0.5% PVA in PBS for the dilution of the horseradish per-
oxidase conjugated anti-human IgA and IgG and six
washes between ELISA procedures. The cut-off for oral
antibody positivity was determined by calculating the
mean plus 3 standard deviations of the absorbance values
obtained from the oral fluid samples of those children
aged between 2 and 10 years after the elimination of out-
liers as described for the determination of seropositivity
cut-off values [23]. Total IgA estimations were performed
on each oral sample to determine the adequacy of the
sample prior to HPV antibody testing, as described previ-
ously[10]. Total oral IgA mean values were 2.3 μg/ml in
children, 4.7 μg/ml in adolescents and 1.8 μg/ml in
adults. There were 3 samples from children with below
normal levels of oral fluid total IgA (<0.5 μg/ml) [24] and
these children were not included in the study. To deter-BMC Infectious Diseases 2006, 6:95 http://www.biomedcentral.com/1471-2334/6/95
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mine the presence of HIV-1 infection, oral samples were
tested was by GACELISA (Wellcozyme HIV-1 + 2, Murex).
HIV-1 testing was anonymous and unlinked so no HIV-1
counselling was done. HIV-1 infection was found in 1/
114 children, 1/78 adolescents and 0/116 adults. CC
patients were not tested for HIV-1 seropositivity.
Statistical analysis
The X2 test of independent proportions was used to deter-
mine the Odds Ratios (OR) and 95% confidence intervals
(95% CI) for the association of antibodies between differ-
ent groups. Agreement between IgA and IgG within the
same sample and between serum and oral fluid antibod-
ies within the same individual was evaluated by Kappa
statistic. If Kappa = 1, then there is perfect agreement and
if Kappa = 0 there is no agreement. A kappa <0.4 indicates
that there is poor agreement, a kappa 0.4–0.75 indicates
fair to good agreement and a kappa > 0.75 indicates excel-
lent agreement. [25].
Results
Oral HPV DNA
All CerviBrush-collected buccal samples were CCR-5 pos-
itive. Extraction controls (phosphate buffered saline, PBS)
were included during all extractions and all were negative
for both CCR-5 and HPV DNA. Oral HPV DNA was
detected in 17/308 buccal specimens from the dental pop-
ulation (5.5%) with the prevalence of oral HPV highest
amongst the children (9/114, 7.9%) then the adolescents
(4/78, 5.1%) and lowest amongst adults (4/116, 3.5%).
The most prevalent type was HPV-13 found in 41.2% (7/
17) of the HPV positive samples or in 2.3% of the partici-
pants. The demographics, oral HPV types and oral HPV-
16, HPV-18 and HPV-11 antibody prevalence of the 17
people infected with oral HPV are shown in Table 1. The
one patient diagnosed with focal epithelial hyperplasia
was infected with HPV-13 (Table 1). There was no appar-
ent gender difference in oral HPV prevalence (P = 0.7).
There were 9 male and 8 females of the 17 individuals
infected with oral HPV (Table 1)
Oral antibodies in children, adolescents and adults
In contrast to the oral HPV prevalence, the prevalence of
oral HPV antibodies was lowest in the children, increased
in adolescents and was highest in adults (Fig 1). Of the
children 15.8% (18/114) and 4.4% (5/114) tested posi-
tive for oral HPV-16 IgA and IgG respectively. For HPV-18
the prevalence was 3.5% (4/114) for both IgA and IgG
and for HPV-11, 6.2% (7/114) and 1.8% (2/114) respec-
tively. Oral antibody prevalence increased in adolescents
where 29.5% (23/78) and 28% (22/78) displayed HPV-
16 IgA and IgG respectively, 29.5% (23/78) and 3.8% (3/
78) HPV-18 IgA and IgG and 21% (16/78) and 14.1%
(11/78) HPV-11 IgA and IgG respectively. The difference
in antibody prevalence between children and adolescents
were significant for HPV-16 IgA (P = 0.01) and IgG (P <
0.001), for HPV-18 IgA (P = 0.001) and for HPV-11 IgA (P
= 0.002) and IgG (P = 0.001). The highest antibody prev-
alence was seen in the adults where 41% (48/116) and
37.9% (44/116) showed HPV-16 IgA and IgG, 25.9% (30/
116) and 8.2% (9/116) HPV-18 IgA and IgG respectively
and 28.5% (33/116) for HPV-11 IgA and IgG (Fig 2). Dif-
ferences were not significant between adult and adoles-
cent antibody prevalence except for HPV-11 IgG (P =
Table 1: Age, gender and prevalence of oral HPV types and oral HPV antibodies in the 17 dental patients with oral HPV infection
Patient 
count
Age 
years
Gender Oral 
HPV 
type
Oral 
lesions
VLP-16 VLP-18 VLP-11
M a l e F e m a l e I g AI g GI g AI g GI g AI g G
14+ 1 3
25+ 1 3
36+ 3 2
46 + 3 2
57+ 1 1
67 + 3 2
78+ 7 2 +
89 + 7 2
91 0+ 1 3
10 13 + 32
11 15 + 31 +
12 15 + 11
13 15 + 13
14 22 + 13 FEH
15 23 + 16 +
16 48 + 13 +
17 52 + 13 + + +
• FEH = Focal epithelial hyperplasiaBMC Infectious Diseases 2006, 6:95 http://www.biomedcentral.com/1471-2334/6/95
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Boxplot analysis of dental patients HPV ELISA OD results Figure 1
Boxplot analysis of dental patients HPV ELISA OD results. Box plot analysis of the optical density values obtained in 
oral antibody ELISA to HPV-16, HV-18 and HPV-11 in dental clinic patients, children, adolescents and adults. Median values, 
depicted by the line in the box, for HPV-16 IgA are 0.03, 0.04 and 0.08 for children, adolescents and adults respectively: for 
HPV-16 IgG 0.29, 0.35, and 0.43 respectively: for HPV-18 IgA 0.02, 0.03 and 0.03 respectively and HPV-18 IgG 0.3, 0.2 and 0.4 
respectively: for HPV-11 IgA 0.02, 0.02, and 0.04 and HPV-11 IgA 0.15, 0.14 and 0.31 respectively
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0.02). Other P values were, HPV-16 IgA P = 0.9, HPV-16
IgG P = 0.16, HPV-18 IgA P = 0.6 and HPV-18 IgG P = 0.4
and HPV-11 IgA P = 0.5. Differences between adult and
children antibody prevalences were all highly significant
(P < 0.001) except for HPV-18 IgG (P = 0.15).
There was low concordance between the prevalence of
oral HPV-16, HPV-18 or HPV-11 IgA and IgG antibodies
within the same sample as determined by kappa (K < 0.4,
data not shown). There were 15/116 (12.9%) adults with
corresponding IgA and IgG to HPV-16, three of these
adults also had corresponding IgA and IgG to HPV-18 and
to HPV-11 and 3 had corresponding IgA to HPV-11 as well
as HPV-16. No adult had corresponding IgA and IgG to
HPV-18 or HPV-11 unless they had corresponding HPV-
16 IgA and IgG antibodies (data not shown).
Oral antibodies stratified by gender
Antibody prevalence in oral fluid was assessed according
to gender in the three age categories of dental clinic partic-
ipants (Fig 3). Amongst the adults more men displayed
HPV-16 and HPV-18 and HPV-11 IgA than females (64%
compared with 26%; 36% compared with 19% and 36%
compared with 23% respectively). The male to female dif-
ferences were significant for HPV-16 IgA (30/47 com-
pared with 18/69, OR 5, 95% CI 2.1–12.1, P < 0.001) and
borderline for HPV-18 IgA (17/47 compared with 13/69,
OR 2.4 95% CI 0.97–6.2, P = 0.04) but not significant for
HPV-11 (17/47 compared with 16/69, OR 1.9, 95% CI
0.8–4.6, P = 0.13). The prevalence of HPV IgG was similar
in men and women (34% compared with 41% for HPV-
16; 8.5% compared with 7.2% for HPV-18 and 28% com-
pared with 29% for HPV-11 (P = 0.5, P = 0.5 and P = 0.9
respectively) (Fig 2). The number of oral antibody posi-
tive children was too low for a gender comparison to be
made except for HPV-16 IgA where the male to female dif-
ference was not significant (11/56 compared with 7/58,
OR 1.63 95% CI 0.6-7-3.9, P = 0.3). For the adolescents
the trend was for more females to display oral HPV IgA
and more males HPV IgG, although differences were not
significant. Oral HPV-16 IgA was found in 31% of female
adolescents and in 27.8% of adolescent men (P = 0.76).
For HPV-18 IgA the prevalences were 33% and 25% (P =
0.42) and HPV-11 IgA 24% and 17% (P = 0.43) for young
women and young men respectively (Fig 3). An apparent
increased prevalence of oral HPV-16, HPV-18 and HPV-11
IgA in female adolescents compared with adult females
was also not significant (Fig 3). Amongst adolescent
females the prevalence of HPV-16, HPV-18 and HPV-11
IgA was 31%, 33.3% and 24% respectively and for adult
females these prevalences were 26%, 18.8% and 23.2%
respectively (P = 0.6, 0.08 and 0.9 respectively).
Antibodies in women from the colposcopy clinic
Amongst the women from the colposcopy clinic, HPV-16
oral IgA was found in 30/44 women (68.2%) and HPV-16
oral IgG in 14/44 (31.8%) women. The prevalence of oral
HPV-16 IgA was significantly higher in these women than
the women from the dental clinic (30/44, 68.2% com-
pared with18/69, 26.1% P = 0.0001) but not for oral
HPV-16 IgG (14/44 31.8%, compared with 28/69, 40.6%
P = 0.35). The prevalence of HPV-16 serum IgA in the col-
poscopy clinic patients was 50%, serum IgG 34.1%. There
was low agreement between the presence of oral or serum
HPV-16 antibodies in the same individual. There was also
low agreement between the presence of HPV-16 IgA or
Antibody prevalence in dental cohort according to gender Figure 3
Antibody prevalence in dental cohort according to 
gender. The prevalence of oral HPV-16, HPV-18 and HPV-
11 antibodies in dental clinic patients, children (child), adoles-
cents (teen) and adults according to gender.
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HPV antibody prevalence in the dental cohort Figure 2
HPV antibody prevalence in the dental cohort. The 
prevalence of HPV-16, HPV-18 and HPV-11 IgA and IgG anti-
bodies in dental clinic patients, children (child), adolescents 
(teen) and adults.
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Table 2: The prevalence of HPV-16 antibodies in CIN patients (Pt) according to their grade of CIN (CIN0, CIN1 or CIN2/3) and HPV-
16 infection at the cervix.
Pt HPV types HPV-16 IgA HPV-16 IgG
no cervical Oral serum oral serum
CIN 0 88 11, 16, 18, 35, 42, 
55
79 16, 18, 31, 35, 55, 
58
■■ ■
87 16, 51, 55 ■
CIN 1 92 16 ■■
85 16, 58, 61 ■■ ■
CIN 2/3 74 16
80 16
86 16 ■
93 16
95 16 ■
122 16 ■■ ■
123 16, 45, 70, 61 ■■
108 16, 45, 70, CP6108 ■
109 16, 51, IS39, 83 ■■
121 16, 68 ■■
99 16, 39 ■■
100 16, 52, 66 ■■
N u m b e r 1 7 9655
% 52.9 35.3 29.4 29.4
CIN 0 103 35 ■■ ■
111 53 ■■
112 58 ■■
90 33, 61 ■■■
75 42, 51, 56 ■
104 51, 56 ■
107 negative ■■
110 negative ■■ ■
120 negative ■■
CIN 1 119 45 ■■
101 51 ■■■■
106 53 ■■
84 56 ■■
78 35, 59
89 35, 62
91 51, 53, 54, 59, 68 ■■ ■
116 52, 33, 35, 58 ■■■■
115 58, 66 ■■
76 negative ■■
114 negative ■■
CIN 2/3 117 35 ■
105 18, 6 ■
113 31, 45 ■■
94 31, 58 ■■
118 33, 45, 58, 66 ■■ ■
82 45, 82 ■■
81 51, 58 ■■ ■
N u m b e r 2 7 2 1 1 691 0
% 77.8 59.3 33.3 37.0
total 44 68.2 50.0 31.8 34.1
Empty cells indicate a negative antibody result
Black boxes indicate a positive antibody resultBMC Infectious Diseases 2006, 6:95 http://www.biomedcentral.com/1471-2334/6/95
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IgG within the same individual (Kappa < 0.4, data not
shown).
The prevalence of HPV-16 antibodies in oral and serum
samples from these women stratified according to the
grade of CIN and the presence of cervical HPV-16 are
shown in Table 2. There were no significant differences
between the prevalence of antibodies in oral or serum
samples from women with cervical HPV-16 infection and
those without. Oral HPV-16 IgA antibody prevalence was
52.6% in women with HPV-16 cervical infection and
68.2% in women with no HPV-16 infection (P = 0.09)
and oral HPV-16 IgG 29.4% and 33.3 % respectively (P =
0.79). For serum antibodies, HPV-16 IgA was found in
35.3% of HPV-16 infected women and in 50% of women
with no HPV-16 (P = 0.12) and HPV-16 IgG found in
29.4% and 34.1% (P = 0.60).
Discussion
The oral HPV types found in this study belong to the
Alpha-papillomavirus genus which includes mucosal and
cutaneous HPV types [26]. The predominant type found
was HPV-13, in 41.2% of the HPV positive isolates from
the dental population. Focal epithelial hyperplasia (FEH)
has been associated with both HPV-13 and HPV-32 [27].
HPV-13 was isolated from the mouth of the one individ-
ual with FEH lesions, supporting this association. The
5.5% (17/308) oral HPV prevalence found in the normal
buccal mucosa of the dental clinic participants is similar
to other studies [3,4,28]. The high prevalence of oral HPV
in children has also been described [29] and was not
reflected by a high oral antibody prevalence indicating
that oral antibodies are possibly elicited elsewhere and
not in the mouth. It must be noted however that we did
not test for antibodies to the majority of the HPV types
found in the mouth. The high prevalence of oral IgA in the
women with CIN and especially in those without cervical
HPV-16 infection is unclear. The apparent lack of con-
cordance between oral and serum antibodies in the
women with CIN confirms previously published data [10]
and possibly indicates the distinct compartmentalisation
of these responses.
The oral sampling of oral fluid for this study was favoura-
bly accepted by the children, adolescents and adults, even
in children as young as one year old. Three oral fluid sam-
ples were discarded because they showed a lower than
normal total IgA level (<0.5 μg/ml). This occurred in chil-
dren < 2 years and was probably a consequence of the
sampling device not remaining in the mouth for the cor-
rect length of time. A significant finding was the increased
prevalence of oral HPV IgA in adult men compared with
women. Gender differences in seropositivity to HPV have
been reported. The prevalence of HPV serum antibodies is
apparently consistently lower in men than in women,
even in men with high risk sexual activity [16,18]. The rea-
son for this has not been elucidated. HPV infection has
been shown to play an important role in all anogenital
cancers with HPV seropositivity in men and women vary-
ing according to the site of HPV infection [30]. The site of
HPV infection could also impact on the HPV oral humoral
responses, both IgA and IgG. Oral IgG in the present study
originated to a certain degree from oral mucosal transu-
date and would reflect serum IgG antibodies [9] but has
also been shown to be locally produced [24]. The signifi-
cant number of women with cervical disease displaying
oral anti-VLP-16 IgA supported a previous study which
suggested that the IgA antibodies arose through the CMIS
as a result of antigenic stimulation at a cervical site [10].
We postulate the site of the HPV infection in the men (and
women) with oral antibodies to be anogenital, based on
our findings in women with cervical neoplasia. In support
of this, almost no HPV-16, HPV-18 and HPV-11 types
were found in the mouth. The role of HPV infection in
cancers at male and female anogenital sites has been
clearly demonstrated [30]. Tonsillar HPV infection and
oral sex have also been shown to be associated with HPV
seroreactivity in men [18] so the tonsils could be the site
of some of the HPV infection in the men in the present
study. The distinct gender differences both in oral and
serum HPV IgA and IgG antibodies require elucidation.
The difference is possibly a consequence both of the site
of infection and the type and extent of immune response
that is elicited. IgG antibodies in the gingival crevice of the
mouth are mainly serum derived and oral IgA locally pro-
duced so the differences could reflect differences in the
humoral responses in systemic and mucosal compart-
ments in men and women.
In the present study, the high prevalence of oral HPV anti-
bodies in adolescents was notable. HPV seropositivity is
related to sexual activity [14] and oral IgG sampled by the
OraSure method, as in the present study, is largely serum
derived. So if the postulated anogenital site of the initia-
tion of oral IgA antibodies is correct, the appearance of
oral HPV antibody probably correlated with the onset of
sexual activity in the adolescents. The low prevalence of
oral fluid HPV antibodies in children correlates with the
low prevalence found in children's sera and substantiated
the premise that oral antibodies are sexually associated as
are serum antibodies.
Conclusion
We believe that sampling oral fluid for HPV antibodies
shows promise as a simple, non-invasive method to test
for the presence of antibody responses to HPV infection.
However larger studies are required to validate oral fluid
antibody sampling as either a surrogate for serum testing
or as a biomarker of anogenital HPV infection. We postu-BMC Infectious Diseases 2006, 6:95 http://www.biomedcentral.com/1471-2334/6/95
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late the site of infection eliciting oral HPV antibodies to be
mainly anogenital. As an adjunct to serology, oral testing
could increase the sensitivity of HPV analysis, covering a
broader range of humoral responses and contribute to our
understanding of the immune response to HPV. It is well
known that HPV serology underestimates genital HPV
infection even when restricted to the same type HPV DNA
as detected in the lesion. Conceivably certain individuals
could mount more effective mucosal responses to HPV
infection than systemic responses and oral IgA testing
could serve as an adjunct to or even replace serum testing
for genital HPV infection in children. A large study is
underway to further investigate oral HPV IgA as a biomar-
ker of genital HPV infection in women.
Most significant was the finding that more men than
women display oral antibodies, considering the opposite
is found for serum responses. Studies are planned to assist
in the further understanding of the mucosal immune
response to HPV in men and the site of the HPV infection
eliciting these responses. The possible association of oral
HPV antibodies with genital HPV infection especially in
adolescents requires further clarification.
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